Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: KDN017
MIFTS: 59

Kidney Cancer

Categories: Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Kidney Cancer

About this section

MalaCards integrated aliases for Kidney Cancer:

Name: Kidney Cancer 12 44 15
Renal Cancer 12 77 30 56 15
Renal Carcinoma 17 74
Kidney Neoplasm 17 74
Malignant Neoplasm of Kidney Except Pelvis 12
Malignant Neoplasm of Kidney 74
Malignant Tumour of Kidney 12
Renal Cell Carcinoma 74
Kidney Carcinoma 6
Kidney Neoplasms 45
Cancer, Kidney 41

Classifications:

MalaCards categories:
Global: Cancer diseases Genetic diseases Rare diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:263
ICD9CM 36 189.0
MeSH 45 D007680
SNOMED-CT 69 93849006
ICD10 34 C64
Sources

Summaries for Kidney Cancer

About this section
MedlinePlus : 44 You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys. Kidney cancer becomes more likely as you age. Risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time. You may have no symptoms at first. They may appear as the cancer grows. See your health care provider if you notice Blood in your urine A lump in your abdomen Weight loss for no reason Pain in your side that does not go away Loss of appetite Tests to diagnose kidney cancer include blood, urine, and imaging tests. You may also have a biopsy. Treatment depends on your age, your overall health and how advanced the cancer is. It might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Kidney Cancer, also known as renal cancer, is related to renal cell carcinoma, nonpapillary and clear cell renal cell carcinoma, and has symptoms including flank pain An important gene associated with Kidney Cancer is MTOR (Mechanistic Target Of Rapamycin Kinase), and among its related pathways/superpathways are MicroRNAs in cancer and LncRNA-mediated mechanisms of therapeutic resistance. The drugs Avastin and Nexavar have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and endothelial.

Disease Ontology : 12 A urinary system cancer that is located in the kidney.

Wikipedia : 77 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Sources

Related Diseases for Kidney Cancer

About this section

Diseases in the Kidney Cancer family:

Kidney Carcinoma in Situ Renal Carcinoma, Familial

Diseases related to Kidney Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 273)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 32.4 GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MET
2 clear cell renal cell carcinoma 30.2 MALAT1 MEG3 MET MIR21 MTOR PVT1
3 melanoma 30.2 GAS5 H19 HOTAIR MALAT1 MEG3 MIR15A
4 small cell cancer of the lung 30.1 HOTAIR MALAT1 MIR21
5 neuroblastoma 29.9 GAS5 H19 HOTAIR MALAT1 MEG3
6 gallbladder cancer 29.9 H19 HOTAIR MALAT1 MEG3
7 leukemia, acute myeloid 29.9 HOTAIR MALAT1 MEG3 MIR21 MTOR
8 liver cirrhosis 29.9 GAS5 HOTAIR MALAT1 MEG3
9 thyroid cancer 29.8 GAS5 H19 HOTAIR MALAT1 MET PVT1
10 bladder cancer 29.8 GAS5 H19 HIF1A-AS2 HOTAIR MALAT1 MEG3
11 pituitary adenoma 29.8 H19 HOTAIR MALAT1 MEG3 MIR15A
12 myeloma, multiple 29.7 GAS5 H19 HOTAIR MALAT1 MEG3 MIR15A
13 esophageal cancer 29.5 GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MEG3
14 ovarian cancer 29.4 GAS5 H19 HOTAIR MALAT1 MEG3 MIR150
15 pancreatic cancer 29.3 GAS5 H19 HOTAIR MALAT1 MEG3 MET
16 colorectal cancer 29.2 GAS5 H19 HIF1A-AS1 HOTAIR KCNQ1OT1 MALAT1
17 gastric cancer 29.1 GAS5 H19 HIF1A-AS2 HOTAIR KCNQ1OT1 MALAT1
18 prostate cancer 29.1 GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MEG3
19 hepatocellular carcinoma 29.0 GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MEG3
20 breast cancer 28.9 EPB41L4A-DT GAS5 H19 HIF1A-AS2 HOTAIR KCNQ1OT1
21 lung cancer 28.9 EPB41L4A-DT GAS5 H19 HIF1A-AS1 HOTAIR KCNQ1OT1
22 childhood multilocular cystic kidney neoplasm 12.1
23 kidney cancer, childhood 12.0
24 kidney carcinoma in situ 12.0
25 renal carcinoma, familial 12.0
26 hereditary leiomyomatosis and renal cell cancer 11.4
27 birt-hogg-dube syndrome 11.3
28 oncocytoma 11.3
29 renal cell carcinoma, xp11-associated 11.2
30 kidney rhabdoid cancer 11.2
31 renal cell carcinoma, papillary, 1 11.1
32 chromophobe renal cell carcinoma 11.1
33 collecting duct carcinoma 11.1
34 kidney benign neoplasm 11.0
35 familial renal papillary carcinoma 11.0
36 wilms tumor 5 11.0
37 mucinous tubular and spindle renal cell carcinoma 11.0
38 rhabdoid cancer 10.9
39 congenital mesoblastic nephroma 10.9
40 hereditary paraganglioma-pheochromocytoma syndromes 10.8
41 beckwith-wiedemann syndrome 10.8
42 von hippel-lindau syndrome 10.8
43 wilms tumor 1 10.8
44 denys-drash syndrome 10.8
45 perlman syndrome 10.8
46 kidney hemangiopericytoma 10.8
47 transitional cell carcinoma 10.8
48 kidney sarcoma 10.8
49 kidney clear cell sarcoma 10.8
50 simpson-golabi-behmel syndrome 10.8

Graphical network of the top 20 diseases related to Kidney Cancer:



Diseases related to Kidney Cancer
Sources

Symptoms & Phenotypes for Kidney Cancer

About this section

UMLS symptoms related to Kidney Cancer:


flank pain
Sources

Drugs & Therapeutics for Kidney Cancer

About this section

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Avastin 19 50 BEVACIZUMAB Genentech July 2009
2
Nexavar 19 50 SORAFENIB TOSYLATE Bayer/Onyx December 2005
3
Proleukin 19 50 ALDESLEUKIN Chiron January 1998
4
Sutent 19 50 SUNITINIB MALATE Pfizer May 2011/ January 2006
5
Torisel 19 50 TEMSIROLIMUS Wyeth May 2007

Drugs for Kidney Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 624)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
2
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
3
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177 70789204
4
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
5
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
6
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 557795-19-4, 341031-54-7 5329102
7
nivolumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 946414-94-4
8
Ipilimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 477202-00-9
9
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Dactinomycin Approved, Investigational Phase 4,Phase 3,Phase 2 50-76-0 457193 2019
11
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
12
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
13
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 284461-73-0 216239 406563
14
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
15
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
16
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 2180-92-9, 38396-39-3 2474
17
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 437-38-7 3345
19
Zoledronic Acid Approved Phase 4,Phase 3,Phase 1,Phase 2 118072-93-8 68740
20
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
21
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
22
Caffeine Approved Phase 4,Phase 1 58-08-2 2519
23
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
24
Dopamine Approved Phase 4,Phase 2,Not Applicable 62-31-7, 51-61-6 681
25
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
26
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
27
Itraconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 84625-61-6 55283
28
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 50-02-2 5743
29
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 1177-87-3
30
Acetaminophen Approved Phase 4,Phase 2,Not Applicable 103-90-2 1983
31
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
32
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
33
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
34
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
35
Oxytetracycline Approved, Investigational, Vet_approved Phase 4 79-57-2 54715139 5280972
36
Epirubicin Approved Phase 4,Phase 1,Phase 2 56420-45-2 41867
37
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
38
Pirarubicin Investigational Phase 4 72496-41-4
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
46 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
47 interferons Phase 4,Phase 3,Phase 2,Phase 1
48 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1906)
# Name Status NCT ID Phase Drugs
1 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. Unknown status NCT01206764 Phase 4 RAD001
2 The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Unknown status NCT01413607 Phase 4
3 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
4 Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
5 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
6 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
7 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
8 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
9 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
10 Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
11 Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Completed NCT01266837 Phase 4 Everolimus
12 Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
13 Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy Completed NCT03323021 Phase 4
14 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
15 Doxycycline In Lymphangioleiomyomatosis (LAM) Completed NCT00989742 Phase 4 Doxycycline;Placebo
16 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
17 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
18 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
19 Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma Recruiting NCT02399124 Phase 4
20 Effects of Anesthesia on Immunity in Cancer Recruiting NCT03514550 Phase 4 Propofol;Sevoflurane
21 Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery Recruiting NCT03824808 Phase 4 Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution;0.9% Sodium Chloride Injection
22 Study of Nivolumab for Advanced Cancers in India Recruiting NCT03444766 Phase 4 Nivolumab
23 QLB and Laparoscopic Nephrectomy, Postoperative Pain and Recovery Recruiting NCT03339284 Phase 4 Dexamethasone sodium phosphate;Ropivacaine Hydrocloride;Sodium Chloride 9mg/mL
24 Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Laparoscopic Hand-assisted Nephrectomy and Robot Assisted Partiel Nephrectomy Recruiting NCT03571490 Phase 4 Ropivacaine;Saline
25 Efficacy of IV Acetaminophen Versus Oral Acetaminophen Recruiting NCT03365622 Phase 4 acetaminophen;Acetaminophen;Placebos;Placebo Oral Tablet
26 Effects of a Neuroscience-based Technique on Post-traumatic Stress Disorder Symptoms, Inflammation, and Survival in Cancer Patients Announced of a Palliative Disease Progression and Their Partners Recruiting NCT03652298 Phase 4
27 An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02596035 Phase 4 Nivolumab
28 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
29 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
30 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
31 Combination Therapy of Anthracyclines for Children With Nephroblastoma Not yet recruiting NCT03892330 Phase 4 Vincristine;Oxytetracycline/ Cyclophosphamide;Liposomal doxorubicin;Doxorubicin;Pharmorubicin;Pirarubicin
32 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4 Everolimus
33 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
34 Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
35 Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy Terminated NCT01486550 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
36 Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Unknown status NCT01099423 Phase 3
37 Exercise for Patients With Renal Cell Cancer Receiving Sunitinib Unknown status NCT00869011 Phase 3
38 Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
39 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3 vincristine sulfate
40 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
41 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium Unknown status NCT02928692 Phase 3 Minocycline;Placebo
42 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
43 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Unknown status NCT01987596 Phase 3
44 Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer Completed NCT00416429 Phase 3 medroxyprogesterone
45 Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer Completed NCT00416871 Phase 3
46 AE-941 in Treating Patients With Metastatic Kidney Cancer Completed NCT00005995 Phase 3 shark cartilage extract AE-941
47 Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer Completed NCT00002737 Phase 3 chemotherapy;isotretinoin
48 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00018941 Phase 3
49 Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney Cancer Completed NCT00002473 Phase 3
50 Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer Completed NCT00005966 Phase 3 thalidomide

Search NIH Clinical Center for Kidney Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: kidney neoplasms

Sources

Genetic Tests for Kidney Cancer

About this section

Genetic tests related to Kidney Cancer:

# Genetic test Affiliating Genes
1 Renal Cancer 30
Sources

Anatomical Context for Kidney Cancer

About this section

MalaCards organs/tissues related to Kidney Cancer:

42
Kidney, Bone, Endothelial, Brain, Prostate, Testes, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Cancer:

20
The Kidney
Sources

Publications for Kidney Cancer

About this section

Articles related to Kidney Cancer:

(show top 50) (show all 2719)
# Title Authors Year
1
Acromegaly associated with GIST, non-small cell lung cancer, clear cell renal cancer, myeloma multiplex, medulla oblongata tumor, adrenal adenoma and follicular thyroid nodules. ( 30742299 )
2019
2
Impact of Perioperative Blood Transfusions on the Outcomes of Patients Undergoing Kidney Cancer Surgery: A Systematic Review and Pooled Analysis. ( 30341027 )
2019
3
Radiomics in Kidney Cancer: MR Imaging. ( 30466904 )
2019
4
Combination therapy for advanced and metastatic kidney cancer. ( 30538301 )
2019
5
Knockdown of ribosomal protein S15A inhibits human kidney cancer cell growth in vitro and in vivo. ( 30569143 )
2019
6
Metformin Use and Kidney Cancer Survival Outcomes: A Systematic Review and Meta-Analysis. ( 30663998 )
2019
7
Systematic review of modifiable risk factors for kidney cancer. ( 30685335 )
2019
8
Surgical treatment of liver metastases from kidney cancer: a systematic review. ( 30685878 )
2019
9
Case-control investigation of occupational lead exposure and kidney cancer. ( 30760604 )
2019
10
Kidney cancer incidence rates in the world from the Cancer Incidence in Five Continents XI. ( 30789667 )
2019
11
Correction to: SEOM clinical guideline for treatment of kidney cancer (2017). ( 30798511 )
2019
12
Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer. ( 30817292 )
2019
13
Examining Public Communication About Kidney Cancer on Twitter. ( 30860867 )
2019
14
Heavy metals, welding fumes, and other occupational exposures, and the risk of kidney cancer: A population-based nested case-control study in three Nordic countries. ( 30903816 )
2019
15
The adjuvant treatment of kidney cancer: a multidisciplinary outlook. ( 30914797 )
2019
16
Post-operative complications increase the risk of long-term chronic kidney disease after nephron sparing surgery in renal cancer patients with normal preoperative renal function. ( 30768877 )
2019
17
Renal Cancer Surgery for Patients without Preexisting Chronic Kidney Disease: Is there a Survival Benefit for Partial Nephrectomy? ( 30694940 )
2019
18
Prolonged survival of renal cancer patients is concomitant with a higher regucalcin gene expression in tumor tissues: Overexpression of regucalcin suppresses the growth of human renal cell carcinoma cells in vitro. ( 30387835 )
2019
19
High expression of TAZ serves as a novel prognostic biomarker and drives cancer progression in renal cancer. ( 30731073 )
2019
20
Specific immune cell and lymphatic vessel signatures identified by image analysis in renal cancer. ( 30737470 )
2019
21
Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2. ( 30745848 )
2019
22
PET imaging in renal cancer. ( 30747736 )
2019
23
Re: Time Trends in Service Provision and Survival Outcomes for Patients with Renal Cancer Treated by Nephrectomy in England 2000-2010. ( 30747866 )
2019
24
Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer. ( 30770799 )
2019
25
Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement. ( 30772357 )
2019
26
Loss of MYBBP1A Induces Cancer Stem Cell Activity in Renal Cancer. ( 30781655 )
2019
27
mTORC1-driven accumulation of the oncometabolite fumarate as a potential critical step in renal cancer progression. ( 30788416 )
2019
28
Renal Cancer is Not Radioresistant: Slowly but Continuing Shrinkage of the Tumor After Stereotactic Body Radiation Therapy. ( 30803362 )
2019
29
CHEK2 Alleles Predispose to Renal Cancer in Poland-In Reply. ( 30816934 )
2019
30
CHEK2 Alleles Predispose to Renal Cancer in Poland. ( 30816943 )
2019
31
Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis. ( 30832444 )
2019
32
Upregulation of LINC00982 inhibits cell proliferation and promotes cell apoptosis by regulating the activity of PI3K/AKT signaling pathway in renal cancer. ( 30840265 )
2019
33
[Pt(O,O'-acac)(γ-acac)(DMS)] Induces Autophagy in Caki-1 Renal Cancer Cells. ( 30845773 )
2019
34
NDNF inhibits the migration and invasion of human renal cancer cells through epithelial-mesenchymal transition. ( 30867731 )
2019
35
IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer. ( 30883740 )
2019
36
Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion. ( 30906803 )
2019
37
Disagreement in risk groups for metastatic renal cancer. ( 30911153 )
2019
38
Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells. ( 30125350 )
2019
39
Do We Truly Care About the Functional Outcomes for Renal Cancer Patients? Multidisciplinarity Is Still Far Away. ( 30237026 )
2019
40
Bimetallic titanocene-gold phosphane complexes inhibit invasion, metastasis, and angiogenesis-associated signaling molecules in renal cancer. ( 30368130 )
2019
41
Fisetin decreases TET1 activity and CCNY/CDK16 promoter 5hmC levels to inhibit the proliferation and invasion of renal cancer stem cell. ( 30411496 )
2019
42
Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. ( 30498230 )
2019
43
Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. ( 30599072 )
2019
44
The role of vascular clamping during robot-assisted partial nephrectomy for localized renal cancer: rationale and design of the CLOCK randomized phase III study. ( 30607928 )
2019
45
Association between age and sex and mortality after adjuvant therapy for renal cancer. ( 30620389 )
2019
46
National trends and disparities of minimally invasive surgery for localized renal cancer, 2010 to 2015. ( 30630732 )
2019
47
VHL regulates NEK1 via both HIF-2α pathway and ubiquitin-proteasome pathway in renal cancer cell. ( 30635121 )
2019
48
Frequency and Predictors of Renal Transplantation Among Patients Rendered Surgically Anephric for Sporadic Renal Cancer. ( 30648561 )
2019
49
Synthesis and biological evaluation of some novel thiobenzimidazole derivatives as anti-renal cancer agents through inhibition of c-MET kinase. ( 30658233 )
2019
50
Therapeutic effect and adverse reaction of sorafenib in the treatment of advanced renal cancer. ( 30675211 )
2019
Sources

Variations for Kidney Cancer

About this section

ClinVar genetic disease variations for Kidney Cancer:

6 (show all 18)
# Gene Variation Type Significance SNP ID Assembly Location
1 MET NM_001127500.2(MET): c.3742T> C (p.Tyr1248His) single nucleotide variant Uncertain significance rs121913247 GRCh37 Chromosome 7, 116423413: 116423413
2 MET NM_001127500.2(MET): c.3742T> C (p.Tyr1248His) single nucleotide variant Uncertain significance rs121913247 GRCh38 Chromosome 7, 116783359: 116783359
3 MET NM_001127500.2(MET): c.3743A> G (p.Tyr1248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913246 GRCh37 Chromosome 7, 116423414: 116423414
4 MET NM_001127500.2(MET): c.3743A> G (p.Tyr1248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913246 GRCh38 Chromosome 7, 116783360: 116783360
5 MET NM_001127500.2(MET): c.3335A> G (p.His1112Arg) single nucleotide variant Pathogenic rs121913243 GRCh37 Chromosome 7, 116417464: 116417464
6 MET NM_001127500.2(MET): c.3335A> G (p.His1112Arg) single nucleotide variant Pathogenic rs121913243 GRCh38 Chromosome 7, 116777410: 116777410
7 MET NM_001127500.2(MET): c.3334C> T (p.His1112Tyr) single nucleotide variant Likely pathogenic rs121913244 GRCh37 Chromosome 7, 116417463: 116417463
8 MET NM_001127500.2(MET): c.3334C> T (p.His1112Tyr) single nucleotide variant Likely pathogenic rs121913244 GRCh38 Chromosome 7, 116777409: 116777409
9 MET NM_001127500.2(MET): c.3803T> C (p.Met1268Thr) single nucleotide variant Likely pathogenic rs121913245 GRCh37 Chromosome 7, 116423474: 116423474
10 MET NM_001127500.2(MET): c.3803T> C (p.Met1268Thr) single nucleotide variant Likely pathogenic rs121913245 GRCh38 Chromosome 7, 116783420: 116783420
11 MTOR NM_004958.3(MTOR): c.7514G> C (p.Arg2505Pro) single nucleotide variant Likely pathogenic rs1057519777 GRCh37 Chromosome 1, 11169361: 11169361
12 MTOR NM_004958.3(MTOR): c.7514G> C (p.Arg2505Pro) single nucleotide variant Likely pathogenic rs1057519777 GRCh38 Chromosome 1, 11109304: 11109304
13 MTOR NM_004958.3(MTOR): c.6667C> A (p.Gln2223Lys) single nucleotide variant Likely pathogenic rs1057519778 GRCh37 Chromosome 1, 11182179: 11182179
14 MTOR NM_004958.3(MTOR): c.6667C> A (p.Gln2223Lys) single nucleotide variant Likely pathogenic rs1057519778 GRCh38 Chromosome 1, 11122122: 11122122
15 MTOR NM_004958.3(MTOR): c.6644C> A (p.Ser2215Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh37 Chromosome 1, 11184573: 11184573
16 MTOR NM_004958.3(MTOR): c.6644C> A (p.Ser2215Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh38 Chromosome 1, 11124516: 11124516
17 MTOR NM_004958.3(MTOR): c.4379T> C (p.Leu1460Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519779 GRCh37 Chromosome 1, 11217299: 11217299
18 MTOR NM_004958.3(MTOR): c.4379T> C (p.Leu1460Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519779 GRCh38 Chromosome 1, 11157242: 11157242

Cosmic variations for Kidney Cancer:

9 (show top 50) (show all 260)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 0
2 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.353T>C p.L118P 3:10146526-10146526 0
3 COSM14380 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.548C>A p.S183* 3:10149871-10149871 0
4 COSM18350 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.256C>T p.P86S 3:10142103-10142103 0
5 COSM17957 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.292T>G p.Y98D 3:10142139-10142139 0
6 COSM14382 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.245G>C p.R82P 3:10142092-10142092 0
7 COSM14305 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.266T>A p.L89H 3:10142113-10142113 0
8 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 0
9 COSM17875 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.234T>G p.N78K 3:10142081-10142081 0
10 COSM17983 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.500G>A p.R167Q 3:10149823-10149823 0
11 COSM18097 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.482G>A p.R161Q 3:10149805-10149805 0
12 COSM14425 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-2A>T p.? 3:10146512-10146512 0
13 COSM17872 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.217C>T p.Q73* 3:10142064-10142064 0
14 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 3:124737785-124737785 0
15 COSM7349320 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1119+1G>T p.? 16:2060814-2060814 0
16 COSM7349613 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.976-1G>A p.? 16:2060669-2060669 0
17 COSM7349594 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2356-1G>C p.? 16:2074199-2074199 0
18 COSM7349602 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1636G>T p.E546* 16:2065555-2065555 0
19 COSM7349619 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.390C>G p.Y130* 16:2054349-2054349 0
20 COSM7349321 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1600-1G>T p.? 16:2065518-2065518 0
21 COSM7349621 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.774+1G>A p.? 16:2056770-2056770 0
22 COSM7349639 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.731G>T p.C244F 16:2056726-2056726 0
23 COSM7349636 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1189C>T p.Q397* 16:2061940-2061940 0
24 COSM6957851 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.541G>A p.V181M 16:2055461-2055461 0
25 COSM7349616 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1717-1G>C p.? 16:2070455-2070455 0
26 COSM1272079 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.3412C>T p.R1138* 16:2080179-2080179 0
27 COSM6943738 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.975+1G>T p.? 16:2058874-2058874 0
28 COSM7349331 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1276G>T p.D426Y 9:132907358-132907358 0
29 COSM6942356 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2287C>T p.Q763* 9:132902709-132902709 0
30 COSM6963117 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1001C>A p.S334* 9:132911481-132911481 0
31 COSM29770 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.508+1G>T p.? 9:132923347-132923347 0
32 COSM7349328 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1835T>A p.L612* 9:132905743-132905743 0
33 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 0
34 COSM10656 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.742C>T p.R248W 17:7674221-7674221 0
35 COSM45243 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.374C>G p.T125R 17:7675995-7675995 0
36 COSM10647 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.404G>T p.C135F 17:7675208-7675208 0
37 COSM44310 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.738G>A p.M246I 17:7674225-7674225 0
38 COSM6922197 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.97-2A>C p.? 17:7676274-7676274 0
39 COSM45135 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.673-1G>T p.? 17:7674291-7674291 0
40 COSM6929752 TBX3 kidney,NS,carcinoma,renal cell carcinoma unclassified c.510G>T p.W170C 12:114681026-114681026 0
41 COSM6979493 STAG2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2096+1G>A p.? 23:124065947-124065947 0
42 COSM6975582 STAG2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1348A>T p.R450* 23:124057909-124057909 0
43 COSM6023628 STAG2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2860C>T p.R954C 23:124081464-124081464 0
44 COSM6963119 SPOP kidney,NS,carcinoma,renal cell carcinoma unclassified c.265T>G p.L89V 17:49619321-49619321 0
45 COSM6964939 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.987-2A>T p.? 22:23833570-23833570 0
46 COSM989 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1130G>A p.R377H 22:23834152-23834152 0
47 COSM1266238 SMARCA4 kidney,NS,carcinoma,renal cell carcinoma unclassified c.3575G>A p.R1192H 19:11033318-11033318 0
48 COSM6975580 SETD2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.4736C>G p.S1579* 3:47062211-47062211 0
49 COSM6947611 SETD2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.863C>A p.S288* 3:47122264-47122264 0
50 COSM4118007 SETD2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.3266G>A p.R1089Q 3:47106061-47106061 0

Copy number variations for Kidney Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 166351 3 10158318 10168746 Mutations VHL Renal cancer
Sources

Expression for Kidney Cancer

About this section
Search GEO for disease gene expression data for Kidney Cancer.
Sources

Pathways for Kidney Cancer

About this section

Pathways related to Kidney Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 38
11.64 MET MIR150 MIR15A MIR17 MIR200B MIR21
2
LncRNA-mediated mechanisms of therapeutic resistance 1
10.03 HOTAIR MEG3
Sources

GO Terms for Kidney Cancer

About this section

Cellular components related to Kidney Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.23 H19 MEG3 MIR150 MIR15A MIR17 MIR191

Biological processes related to Kidney Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cellular response to hypoxia GO:0071456 9.65 MALAT1 MIR17 MTOR
2 negative regulation of angiogenesis GO:0016525 9.63 MIR15A MIR200B MIR21
3 miRNA mediated inhibition of translation GO:0035278 9.54 MIR15A MIR17 MIR21
4 chromatin silencing GO:0006342 9.52 HOTAIR KCNQ1OT1
5 negative regulation of stress fiber assembly GO:0051497 9.51 MET MIR21
6 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.49 MIR15A MIR21
7 positive regulation of endothelial cell differentiation GO:0045603 9.43 MIR150 MIR21
8 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.4 MIR17 MIR21
9 regulation of protein kinase B signaling GO:0051896 9.32 MIR21 MTOR
10 positive regulation of metalloendopeptidase activity GO:1904685 9.26 MIR17 MIR21
11 gene silencing by miRNA GO:0035195 9.23 H19 MEG3 MIR150 MIR15A MIR17 MIR191
12 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.16 MIR17 MIR21
13 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 8.96 MET MIR21

Molecular functions related to Kidney Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR150 MIR15A MIR17 MIR191 MIR200B MIR21
Sources

Sources for Kidney Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....